In conjunction with Anastasiou's appointment, the company has also appointed Troy Ignelzi as a Class III director, filling the vacancy left by Anastasiou's resignation from the board. Ignelzi, who currently serves as Chief Financial Officer of Rapport Therapeutics, has extensive experience in finance and operations within the biotechnology sector. His addition to the board is anticipated to bring valuable insights and expertise to Harmony's governance.
Additionally, the company has nominated Geno J. Germano for election to the board at the upcoming 2026 Annual Meeting of Shareholders. Germano is a seasoned executive with a strong background in the pharmaceutical industry, having held senior roles at major companies such as Pfizer and Johnson & Johnson. His nomination reflects Harmony's commitment to strengthening its leadership team as it navigates the complexities of the biotechnology landscape.
These leadership changes come at a pivotal time for Harmony Biosciences, as the company aims to advance its mission of developing innovative treatments for patients with central nervous system disorders. The board has expressed confidence that these appointments will enhance the company's strategic direction and operational effectiveness, ultimately benefiting shareholders and stakeholders alike.
